Click here for slides on this topic


Stroke

Condition caused by damage to blood vessels in the brain; may cause loss of ability to speak or to move parts of the body. A cerebrovascular disease.
The following content matched the glossary term: Stroke

Association between intensification of metformin treatment with insulin vs sulfonylureas and CV events and all-cause mortality among patients with diabetes

Top

Roumie CL, Greevy RA, Grijalva CG, et al. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA. 2014;311(22):2288-2296.

Changes in diabetes-related complications in the United States, 1990–2010

Top

Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med. 2014;370:1514-1523.

Glycated hemoglobin measurement and prediction of cardiovascular disease

Top

The Emerging Risk Factors Collaboration. Glycated hemoglobin measurement and prediction of cardiovascular disease. JAMA. 2014;311(12):1225-1233.

Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus

Top

Lincoff AM, Tardiff J-C, Schwartz GG, et al; for the AleCardio Investigators. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus. The AleCardio randomized clinical trial. JAMA.. 2014. doi:10.1001/jama.2014.3321.

American Heart Association (AHA) Scientific Sessions 2012

Top

Exclusive coverage of late-breaking data from the American Heart Association Scientific Sessions, November 3-7, 2012 in Los Angeles, California are featured in this issue of OnsiteInsight®.

Clinical Insights April 2013

Top

The latest diabetes literature exploring diabetes guidelines, diabetes treatment, diabetes management, and diabetes prevention with commentary from diabetes experts.

OnsiteInsight November 2012

Top

The latest diabetes literature exploring diabetes guidelines, diabetes treatment, diabetes management, and diabetes prevention with commentary from diabetes experts.

HPS2-THRIVE randomized placebo-controlled trial in 25,673 high-risk patients of ER niacin/laropiprant

Top

HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25,673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34(17):1279-1291. Residual risk for cardiovascular disease is seen among many high-risk patients despite LDL-C lowering with statins, and controlling blood pressure and diabetes. Niacin (nicotinic acid) is commonly prescribed as an add-on to statin therapy for incremental lowering of LDL-C, apoB, Lp(a), and triglycerides (TG); and incremental increasing of HDL-C and apoA1.

Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus

Top

Patil HR, Al Badarin FJ, Al Shami HA, et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol. 2012;110:826-833. This meta-analysis from Patil and colleagues provides insights into the effects of DPP-4 inhibitors on cardiovascular (CV) events, and is the first adequately powered study that shows a class-wide effect for DPP-4 inhibitors in decreasing CV event risk over long-term treatment (≥24 weeks).

1 2 3 4 5 6 7 8 9 10  ... Next 

Slide Library Results

Search Results for: Stroke Slides Found: 275
Incidence of Type 2 Diabetes-Related Vascular Disease in Four Ethnic Groups
Relationship Between Flow-Mediated Brachial Artery Dilation and Weight Loss After Lifestyle Modification
Changes in Flow-Mediated Brachial Artery Dilation After 6 Months of Lifestyle Modification
Association of Stroke With Baseline Glycemic Factors in Patients With Type 2 Diabetes Followed for 3.5 Years
WESDR: Hazard Ratios of Cause-Specific Mortality and Glycemia in Patients With Older-Onset Diabetes
Meta-Analysis: A1C and CVD in Type 2 Diabetes
Results From Statin Trials for Patients With Diabetes
Pioglitazone Decreases Carotid IMT Independent of Glycemic Control in Patients With Type 2 Diabetes
DIGAMI 2: Cumulative Mortality After Acute MI in Type 2 Diabetes
PROactive: Objective/Endpoints
PROactive: Time to Primary Composite Endpoint
PROactive: Time to Main Secondary Composite Endpoint (Death, Nonfatal MI, or Stroke)
DCCT/EDIC: Incidence of Nonfatal MI, Stroke, or Death
SPARCL: Primary Outcome of Fatal or Nonfatal Stroke
SPARCL: First Events
TNT: Intensive Atorvastatin Treatment Reduces Cardiovascular Events in Patients With CHD and Diabetes
Global Impact of Hyperglycemia: Ischemic Heart Disease and Stroke Mortality
Hope: Design, Hypothesis, and Baseline Demographics
Compelling Indications for Hypertension Drug Classes
Microalbuminuria Predicts CV Risk at Levels Below Current Definition
Compelling Indications for Hypertension Drug Classes (1 of 2)
Elevated Risk of CVD Prior to Clinical Diagnosis of Type 2 Diabetes
MICRO-HOPE: ACEI Reduces Risk of Nephropathy and CHF in Patients With Type 2 Diabetes
Stroke Risk in Type 2 Diabetes: First 5 Years After Beginning Treatment
Age-Standardized Stroke Rates in Newly Treated Diabetes vs Control
Stroke Risk by Age in Type 2 Diabetes: First 5 Years After Starting Treatment
Cardiovascular Impact of Pioglitazone Therapy: A Meta-analysis
Pioglitazone Reduces the Risk of Hospitalization for AMI
Steno-2: Effect of Multifactorial Intervention on CV Events in Type 2 Diabetes
ACCORD: Study Design
ACCORD: Results
ADVANCE: Study Design
ADVANCE Trial: Intensive Blood Glucose Control in Patients With Type 2 Diabetes
ACCORD Trial: Intensive Blood Glucose Control in Patients With Type 2 Diabetes
ACCORD Trial: CV Events With Intensive Blood Glucose Control
UKPDS: Intensive SU-Insulin vs Conventional Therapy: Any Diabetes Endpoint
UKPDS: Intensive Metformin vs Conventional Therapy: Diabetes Endpoints
UKPDS: Intensive SU-Insulin vs Conventional Therapy: Myocardial Infarction
UKPDS: Intensive Metformin vs Conventional Therapy: Myocardial Infarction
UKPDS: Intensive SU-Insulin vs Conventional Therapy: Death From Any Cause
UKPDS: Intensive Metformin vs Conventional Therapy: Death From Any Cause
POPADAD Trial: Causes of Death in Patients With Diabetes According to
POPADAD Trial: Effect of Antioxidant Use on Events in Patients With Diabetes
POPADAD Trial: Effect of Aspirin Use on Events in Patients With Diabetes
PROactive 10 Substudy: Time to CV Death, Nonfatal MIa, Nonfatal Stroke
PROactive 10 Substudy: Time to All-Cause Mortality, Nonfatal MIa, Nonfatal Stroke, or ACS
VADT: Comparing Intensive With Standard Glucose Therapy, Primary Outcome
ACCORD-MIND: Relationship Between Glycemia Status, CVD, Stroke, Smoking Status, and Cognitive Test Scores
HEART2D: Primary Outcome Vs Days in Trial by Treatment Strategy
Risk of Dementia, Alzheimer’s Disease, and VaD Related to Borderline Diabetes and Diabetes by Blood Glucose Levels
PROactive 10 Substudy: Time to First Event from MACE Endpoint
RECORD: CV Death and Hospitalization
RECORD: Time to Primary Endpoint
RECORD: Bone Fracture Rates in Upper and Distal Lower Limbs
Meta-Analysis: Intensive vs Standard Glucose Treatment on A1C Concentration at Follow-Up
Meta-Analysis: Intensive vs Standard Glucose Treatment on Non-Fatal Myocardial Infarc
Meta-Analysis: Intensive vs Standard Glucose Treatment on CHD
Meta-Analysis: Conclusion
ACCORD: A1C and Mortality Risk
ACCORD: Annual Incidence of Hypoglycemia in the Intensive Versus Standard Treatment Groups
ACCORD: Hypoglycemia and Mortality
VADT: Primary Endpoint
VADT: Effect of BMI on Rates of Severe Hypoglycemia
ACCORD LIPID: Effects of Combination Statin + Fibrate Therapy
ACCORD LIPID: Effects of Combination Statin + Fibrate Therapy
ACCORD BP: Effects of Intensive BP-Control on Type 2 Diabetes
ACCORD BP: Effects of Intensive BP-Control on Type 2 Diabetes
AHA Heart Disease and Stroke Statistics: Diabetes Prevalence
Incidence of CVD in Patients With Type 2 Diabetes and No CVD History
CVD Event Prediction in Patients With Type 2 Diabetes and No CVD History
ACCORD Substudy: Impact of Frequent and Unrecognized Hypoglycemia on Mortality—Design
TINSAL-T2D Trial: Baseline Characteristics
ORIGIN Glargine Trial: Primary and Secondary Outcomes
ORIGIN Glargine Trial: Eligibility Criteria and Trial Profile
ORIGIN Glargine Trial: Baseline Characteristics (1 of 2)
ORIGIN Glargine Trial: Baseline Characteristics (2 of 2)
ORIGIN Glargine Trial: Insulin Use During Trial
ORIGIN Glargine Trial: A1C, FPG During Trial
ORIGIN Glargine Trial: First Coprimary Composite CV Outcome—CV Death, Nonfatal MI, or Nonfatal Stroke
ORIGIN Glargine Trial: Second Coprimary Composite CV Outcome—CV Death, Nonfatal MI, Nonfatal Stroke, Revascularization, or Hospitalized Heart Failure
ORIGIN Glargine Trial: Secondary Outcomes
ORIGIN Glargine Trial: Secondary Outcome—Cancer Incidence
ORIGIN Glargine Trial: Hypoglycemia
ORIGIN Glargine Trial: Weight Change
ORIGIN Glargine Trial: Conclusions
ORIGIN Omega-3 Fatty Acid Trial: Design
ORIGIN Omega-3 Fatty Acid Trial: Primary and Secondary Outcomes
ORIGIN Omega-3 Fatty Acid Trial: Additional Outcomes
ORIGIN Omega-3 Fatty Acid Trial: Eligibility Criteria and Trial Profile
ORIGIN Omega-3 Fatty Acid Trial: Baseline Characteristics (1 of 2)
ORIGIN Omega-3 Fatty Acid Trial: Baseline Characteristics (2 of 2)
ORIGIN Omega-3 Fatty Acid Trial: Primary Outcome—CV Death
ORIGIN Omega-3 Fatty Acid Trial: Secondary Outcomes
ORIGIN Omega-3 Fatty Acid Trial: Mean Change in Lipids
ORIGIN Omega-3 Fatty Acid Trial: Conclusions
Vascular Risk Associated with Medication-Related Hypoglycemia: Design
Cumulative Incidence of CVD: Hypoglycemia Group vs Control
Cumulative Incidence of Microvascular Complications: Hypoglycemia Group vs Control
Health Consequences of Obesity
Medical Comorbidities Associated with Obesity
JUPITER: Design
JUPITER Analysis: Design
JUPITER Analysis: Risk Reduction With Rosuvastatin ≥1 Major Diabetes Risk Factor*
JUPITER Analysis: Risk Reduction With Rosuvastatin No Major Diabetes Risk Factor*
JUPITER: Statin Therapy for Primary Prevention of Cardiovascular Disease—Rationale
JUPITER: Study Design
JUPITER Results: Primary Endpoint
JUPITER Results: Components of Primary Endpoint
Key Facts: Awareness and Treatment of Uncontrolled Hypertension in US Adults, NHANES 2003-2010
Pooled Analysis: Mortality Among Normal and Overweight/Obese Subjects with Diabetes
Pooled Analysis: Mortality Rates Among Normal and Overweight/Obese Subjects with Diabetes
Meta-analysis: Effects of DPP-4 Inhibitors on CV Events Design
Meta-analysis: Effects of DPP-4 Inhibitors on CV Events Results for Primary Endpoint
SOS Post-hoc Analysis: Effect of Bariatric Surgery on CV Events
SOS Post-hoc Analysis: Stroke in Obese Subjects with Type 2 Diabetes
Diabetic Retinopathy and Incident CV Events in ACCORD: Results
Diabetes Heart Study: CAC and CVD Mortality
PREDIMED: Mediterranean Diet for Primary Prevention of CVD
PREDIMED: Primary Endpoint Rate
PREDIMED: Secondary Endpoint Events
PREDIMED: Primary Endpoint Events
ACCORD: Death from Any Cause
HPS2-THRIVE: Niacin +Laropiprant for Vascular Risk Reduction
HPS2-THRIVE: Baseline Characteristics
AIM-HIGH: Design
AIM-HIGH: Baseline Characteristics
AIM-HIGH: Rate of the Primary Endpoint
AIM-HIGH: Rate of Secondary Endpoints
ORIGIN-GRACE: Major Cardiovascular Events
ORIGIN-GRACE: Summary of Findings
Risk and Prevention Study: Design
Risk and Prevention Study: Secondary Endpoints
ORIGIN-GRACE: Eligibility Criteria and Trial Profile
ESH/ESC Hypertension Guidelines: BP Goals for Hypertensive Patients
ESH/ESC Hypertension Guidelines: Hypertension Treatment for Patients With Cerebrovascular Disease
ESH/ESC Hypertension Guidelines: Hypertension Treatment for Patients With Atherosclerosis, Arteriosclerosis, and PAD
Look AHEAD: No Reduction in CV Events with Lifestyle Changes
Look AHEAD: No Reduction in Secondary CV Outcomes with Lifestyle Changes
Look AHEAD: Primary Outcome, Participant Characteristics
BP Rates and All-Cause Mortality in Newly Diagnosed Type 2 Diabetes: Design
BP Rates and All-Cause Mortality in Newly Diagnosed Type 2 Diabetes: Results
Meta-Analysis: Risk for New-Onset Diabetes and CV Events with Intensive- Vs Moderate Dose Statins
ALTITUDE: No Reduction in CV, Renal Events with Aliskiren
ONTARGET: Similar CV Outcomes with Ramipril, Telmisartan, and Their Combination
SAVOR-TIMI 53: No Increase in CV Events with Saxagliptin in Patients With or At Risk for CVD Secondary Endpoint
SAVOR-TIMI 53: Design
EXAMINE: No Increase in CV Events with Alogliptin Primary Endpoint
EXAMINE: No Increase in CV Events with Alogliptin Secondary Endpoint
EXAMINE: Design
ACC/AHA Cholesterol Guidelines 2013: Statin Benefit Groups for ASCVD Prevention
ACC/AHA Cholesterol Guidelines 2013: ASCVD Statin Benefit Group 1: Secondary Prevention
ACC/AHA Cholesterol Guidelines 2013: ASCVD Statin Benefit Group 1: Primary Prevention LDL-C 190 or Higher
ACC/AHA Cholesterol Guidelines 2013: ASCVD Statin Benefit Group 3: Primary Prevention Diabetes
ACC/AHA Cholesterol Guidelines 2013: ASCVD Statin Benefit Group 4: Primary Prevention With 10-Yr ASCVD Risk 7.5% or Higher (No Diabetes)
ACC/AHA Cholesterol Guidelines 2013: The Argument Against LDL-C, Non-HDL-C Targets
ACC/AHA Cholesterol Guidelines 2013: Role of Biomarkers & Imaging Tests
ACC/AHA Cholesterol Guidelines 2013: LDL-C, Non-HDL-C Targets
ACC/AHA Cholesterol Guidelines 2013: Statin Therapy for Secondary Prevention
ACC/AHA Cholesterol Guidelines 2013: Statin Therapy for Primary Prevention: LDL-C 190 or Higher
ACC/AHA Cholesterol Guidelines 2013: Statin Therapy for Primary Prevention: Diabetes & LDL-C 70-189
ACC/AHA Cholesterol Guidelines 2013: Statin Therapy for Primary Prevention: LDL-C 70-189, No Diabetes
ACC/AHA Cholesterol Guidelines 2013: Heart Failure and Hemodialysis
ACC/AHA Cholesterol Guidelines 2013: High-Intensity Statin for Secondary ASCVD Prevention
ACC/AHA Cholesterol Guidelines 2013: Secondary ASCVD Prevention for Age >75 Years
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Secondary Prevention: Age 75 Years or Younger
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Secondary Prevention: Age 75 and Older
ACC/AHA Cholesterol Guidelines: Primary ASCVD Prevention for LDL-C 190 or Higher
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Primary ASCVD Prevention: Age 40-75 With Diabetes or LDL 190 or Higher
ACC/AHA Cholesterol Guidelines 2013: Statin Initiation for Primary ASCVD Prevention: Age 40-75, LDL 70-189, No Diabetes
ACC/AHA Cholesterol Guidelines 2013: Primary ASCVD Prevention in Individuals With Diabetes
ACC/AHA Cholesterol Guidelines 2013: Primary ASCVD Prevention in Individuals With 70-189, No Diabetes
ACC/AHA Cholesterol Guidelines 2013: Primary ASCVD Prevention for Individuals Not in A Statin Benefit Group
ACC/AHA Cholesterol Guidelines 2013: 10-Yr ASCVD Risk Assessment Calculator: Primary Prevention
ACC/AHA Cholesterol Guidelines 2013: Statin Safety Recommendations: Maximizing Statin Safety
ACC/AHA Cholesterol Guidelines 2013: Statin Safety Recommendations: CK & ALT
ACC/AHA Cholesterol Guidelines 2013: Statin Safety Recommendations: Statin Dosing
ACC/AHA Cholesterol Guidelines 2013: Statin Safety Recommendations: Muscle Symptoms
ACC/AHA Cholesterol Guideline 2013: Statin Safety Recommendations: Cognitive Impairment
ACC/AHA Cholesterol Guidelines 2013: Nonstatin Safety Recommendations: Niacin
ACC/AHA Cholesterol Guidelines 2013: Nonstatin Safety Recommendations: Bile-Acid Sequestrants & Ezetimibe
ACC/AHA Cholesterol Guidelines 2013: Nonstatin Safety Recommendations: Fibrates
ACC/AHA Cholesterol Guidelines 2013: Nonstatin Safety Recommendations: Omega-3 Fatty Acids
ACC/AHA Cholesterol Guidelines 2013: Guidance on Nonstatin Therapies
ACC/AHA Cholesterol Guidelines 2013: Monitoring & Optimizing Statin Therapy
ACC/AHA Cholesterol Guidelines 2013: Insufficient Response to Statin Therapy
AHA/ACC/TOS Obesity Guidelines: CVD and All-Cause Mortality With High BMI
AleCardio: Time to First Occurrence of Any Part of the Composite of CV Mortality, Nonfatal MI, or Nonfatal Stroke With Aleglitazar Vs Placebo
AleCardio: Design
US Adults Diagnosed Diabetes | Diabetes Slides | NDEI
Diabetes Complications Decreased in US | Diabetes Slides | NDEI
Diabetes Complications in US Diagnosed or Undiagnosed | NDEI
Diabetes Complications Relative Risks US Adults | NDEI
A1C CVD Outcomes in Adults Without Diabetes | Diabetes Slides | NDEI
A1C No Benefit CVD Risk Predication in Adults Without Diabetes | NDEI
ACC AHA Lifestyle Guidelines Sodium Potassium CHD CVD | NDEI
ACC/AHA Cholesterol Guidelines 2013: Estimated 10-Yr ASCVD Risk Guides Statin Therapy
IDF Type 2 Diabetes Guidelines In-Patient Critically Ill | NDEI
Type 2 Diabetes Alzheimer Disease | NDEI
Insulin Sulfonlyrea Added to Metformin CVD Mortality | NDEI
Metformin + Insulin or Sulfonylurea CVD Mortality | NDEI
Metformin + Insulin or Sulfonylurea CVD Mortality Design | NDEI
Evidence for Lower SBP Target for Older Adults JNC 8 Guidelines | NDEI
JNC 8 Guidelines First-Line Antihypertensive Therapy PPT | NDEI
JNC 8 Guidelines First-Line Antihypertensive Therapy for Black Patients | NDEI
JNC 8 SBP Goal Older Adults Disagreement PPT | NDEI
SHEP & HYVET Results Consistent With Epidemiologic Data JNC 8 | NDEI
SAVOR TIMI 53 Pancreatitis Cancer Saxagliptin DPP-4 | NDEI
Statin Potency New-Onset Diabetes Risk | NDEI
Statin Potency & Type 2 Diabetes Risk | NDEI
Diabetes Macrovascular Complications US Adults 2012 | NDEI
High-Potency Statins & Increased Diabetes Risk Secondary Prevention | NDEI
RECORD Rosiglitazone Cardiovascular Effects Slides | NDEI
Higher CV Risk With Metformin + Sulfonylurea Vs DPP-4 Inhibitor | NDEI
Edinburgh Type 2 Diabetes Study Severe Hypoglycemia Slide PPT | NDEI
Edinburgh Type 2 Diabetes Hypoglycemia Macrovascular Slides PPT | NDEI
Edinburgh Type 2 Diabetes Inflammation Doesn't Influence Hypoglycemia Slides PPT | NDEI
ADVANCE-ON Type 2 Diabetes Primary Outcomes Intensive Glucose Slide | NDEI
ACCORD BP Post-hoc Analysis: Primary Outcome by Waist/Height Quartiles
Reduction in SBP Lowers Cardiovascular Risk in Type 2 Diabetes PPT | NDEI
BP-Lowering Treatment & Macrovascular Outcomes Type 2 Diabetes | NDEI
ELIXA No Cardiovascular Risks Lixisenatide GLP-1 CV Safety | NDEI
ELIXA Cardiovascular Safety Outcomes for Lixisenatide GLP-1 | NDEI
TECOS Sitagliptin Cardiovascular Safety High-Risk Type 2 Diabetes DPP-4 | NDEI
TECOS Cardiovascular Outcomes Sitagliptin DPP-4 | NDEI
Efficacy and Safety of Saxagliptin in Older Adults in SAVOR-TIMI 53
No Increased Ischemic Events With Saxagliptin Vs Placebo in Older Adults in SAVOR-TIMI 53
Mean A1C Reduction With Saxagliptin in Older Adults in SAVOR-TIMI 53
Blood Pressure Targets Type 2 Diabetes AHA ADA Guidelines | NDEI
IMPROVE-IT Ezetimibe Simvastatin Reduces CV Events Type 2 Diabetes | NDEI
Ezetimibe/Simvastatin Reduces MI & Stroke Type 2 Diabetes IMPROVE-IT | NDEI
Combo Ezetimibe/Simvastatin LDL-C Type 2 Diabetes IMPROVE-IT | NDEI
Sitagliptin Not Associated With Heart Failure in TECOS Type 2 Diabetes | NDEI
SAVOR-TIMI 53: No Increase in CV Events with Saxagliptin in Patients With or At Risk for CVD
EMPA-REG OUTCOME Empagliflozin CV Death Reduced Type 2 Diabetes | NDEI
Empagliflozin Reduces Death Type 2 Diabetes EMPA-REG OUTCOME EASD | NDEI
EMPA-REG OUTCOME Empagliflozin Heart Failure Type 2 Diabetes EASD | NDEI
EMPA-REG OUTCOME Empagliflozin A1C High-Risk Type 2 Diabetes | NDEI
Empagliflozin Safety Adverse Events Type 2 Diabetes EMPA-REG OUTCOME | NDEI
EMPA-REG OUTCOME Design Empagliflozin SGLT2 Type 2 Diabetes | NDEI
ACCORD BP Post-hoc Analysis: Design
ACCORD BP Post-hoc Analysis: Secondary Outcomes by Waist/Height Quartiles
ACCORD BP Post-hoc Analysis:Outcomes by Treatment Group, Waist-to-Height Quartiles
Statin Therapy Recommendations for Type 2 Diabetes ADA Guidelines | NDEI
CHD Screening & Treatment ADA Diabetes Guidelines | NDEI PPT
Type 2 Diabetes Is Associated With Cardiovascular Outcomes | NDEI
ACCELERATE Evacetrapib Does Not Lower CV Events in High-Risk Patients | NDEI
ACCELERATE Evacetrapib Doubles HDL-C & Lowers LDL-C CETP | NDEI
ACCELERATE CETP Inhibitor Trial Ended Early Due to Futility
HOPE-3 Primary Prevention for Individuals at Intermediate CV Risk
HOPE-3 Statin Therapy for Intermediate CV Risk Reduction PPT | NDEI
HOPE-3 CV Event Reduction With Rosuvastatin Vs Placebo PPT | NDEI
HOPE-3 LDL & Lipoprotein Reductions With Rosuvastatin Vs Placebo | NDEI
HOPE-3 Safety of Rosuvastatin Vs Placebo PPT | NDEI
HOPE-3 Incidence Diabetes With Rosuvatatin Vs Placebo PPT | NDEI
HOPE-3 CV Event Reduction With Antihypertensive Therapy PPT | NDEI
HOPE-3 BP Reductions With Candesartan/HCTZ Vs Placebo PPT | NDEI
HOPE-3 Safety of Candesartan/HCTZ Vs Placebo BP PPT | NDEI
HOPE-3 Cholesterol- and BP-Lowering for Intermediate CV Risk Reduction | NDEI
HOPE-3 Lipid- & BP-Lowering Therapy for Primary Prevention PPT | NDEI
HOPE-3 Lipid- & BP-Lowering Intermediate Risk CV Events PPT | NDEI
Lipoprotein Screening in Children & Adolescents NLA Cholesterol Guidelines | CCMD
ASCVD Risk Assessment in Older Adults NLA Cholesterol Guidelines | CCMD
HOPE-3 BP-Lowering Arm: Statin Therapy for Intermediate CV Risk Reduction
LEADER Design Cardiovascular Safety Study Liraglutide CVOT PPT | NDEI
Liraglutide Reduced CV Events in LEADER CV Outcomes Trial PPT | NDEI
Liraglutide Reduced CV & All-Cause Death LEADER CV Outcomes Trial | NDEI
Liraglutide Cardiovascular Outcomes Trial LEADER Heart Failure PPT | NDEI
Liraglutide Reduces Microvascular Events LEADER CVOT Diabetes PPT | NDEI
LEADER Cardiovascular Safety of Liraglutide CVOT PPT | NDEI
Empagliflozin Reduces Kidney Disease in EMPA-REG OUTCOME CVOT | NDEI
Empagliflozin Renal Outcomes in EMPA-REG OUTCOME CVOT | NDEI
IRIS Design Pioglitazone Effect on Cerebrovascular Disease Stroke PPT | NDEI
IRIS Pioglitazone Lowers Risk for Stroke and TIA Vs Placebo PPT | NDEI
IRIS Pioglitazone Lowers Rate of Progression to Diabetes Vs Placebo | NDEI
IRIS Safety of Pioglitazone Vs Placebo After Stroke or TIA PPT | NDEI